This study examined the potential of engineered gelatin-based nanoparticulate vectors for systemic delivery of therapeutic genes to human solid tumor xenografts in vivo. Plasmid DNA encoding for the soluble form of the extracellular domain of vascular endothelial growth factor receptor-1 (VEGF-R1 or sFlt-1) was encapsulated in the control and poly(ethylene glycol) (PEG)-modified gelatin-based nanoparticles. When the plasmid DNA was delivered in PEG-modified thiolated gelatin nanoparticles, highest levels of sFlt-1 expression was observed in vitro in MDA-MB-435 human breast adenocarcinoma cell line. In addition, upon intravenous administration in female Nu/Nu mice bearing orthotopic MDA-MB-435 breast adenocarcinoma xenografts, efficient in vivo expression of sFlt-1 plasmid DNA was confirmed quantitatively by enzyme-linked immunosorbent assay and qualitatively by Western blot analysis. The expressed sFlt-1 was therapeutically active as shown by suppression of tumor growth and microvessel density measurements. The results of this study show that PEG-modified gelatin-based nanovectors can serve as a safe and effective systemically administered gene delivery vehicle for solid tumor.
Introduction
A solid tumor arises as a consequence of multiple genomic alterations in individual cells. Clonal selection generates completely distinct genetic cell populations with different growth kinetics, differentiation, apoptosis, invasive properties and metastatic potential. 1 The molecular pathophysiological information obtained from the understanding of genetic alterations has opened new avenues, based on exogenous delivery of therapeutic genes, for the treatment of neoplastic diseases. Gene therapy strategies for solid tumors using either direct gene administration (in vivo) or removing cells for transformation (ex vivo) can be divided into methods that restore cellular growth control, confer drug sensitivity, induce antitumor immunity or inhibit angiogenesis. 2 The major difficulty in systemic gene therapy, however, is a need for safe and effective vector system that can deliver the gene to the target tissue and cells and allow for expression of the protein of interest over. 3 For antiangiogenic gene therapy, vascular endothelial growth factor (VEGF) is one of the most important regulators of tumor neo-vascularization and is overexpressed by most types of cancers. 4 The proangiogenic effects of VEGF are modulated by binding to the high affinity tyrosine kinase receptors present on the endothelial cells, specifically the Flt-1 and Flk-1/KDR receptors. 5 The soluble form of VEGF receptor (sFlt-1) can be used as a potent therapeutic agent for antiangiogenic gene therapy. 6 The plasmid psFlt-1/pcDNA3 contains the gene sequence encoding for the extracellular domain of Flt-1 VEGF receptor. When expressed in cells, the sFlt-1 plasmid results in the formation of soluble FMS-like tyrosine kinase receptor 1, which is a variant of VEGF receptor lacking the transmembrane and cytoplasmic domains. As a decoy receptor, the expressed sFlt-1 has shown angiostatic activity by sequestering VEGF produced by tumor cells. 7 It also blocks the VEGF receptor signal transduction by forming a heterodimer with the receptor. [8] [9] [10] [11] Successful use of adenoviral vector for sFlt-1-expressing plasmid DNA delivery to tumorbearing animals has already been reported in a number of publications. [12] [13] [14] [15] For systemic gene delivery to tumor mass, viral and non-viral vectors have been used. Although viral vectors are efficient, they have been plagued with serious toxicity concerns. 16 Non-viral vectors for gene delivery applications are increasingly popular owing to several advantages, which include lack of toxicity, no upper limit on the plasmid DNA size, and ease of manufacture. An ideal vector for systemic gene therapy needs to be inert, whereas in circulation and capable of transfecting the target tissue. The vector used should have sufficiently small size and stability, minimal aggregation in blood, can efficiently target cells, disassemble and release the DNA upon cellular internalization, and allow for nuclear import of DNA. 17 We have previously shown that type B gelatin (pI ¼ B4.5) nanoparticles can safely and successfully transfect tumor mass in vivo. 18 In order to enhance the intracellular delivery potential of gelatin, we have synthesized thiolated gelatin (SHGel) by covalent modification of the epsilon-amino groups of gelatin with 2-iminothiolane. Nanoparticles were then prepared with thiolated gelatin using a mild solvent exchange method that has been optimized in our laboratory. 19, 20 The rationale for using thiolated gelatin was to achieve a nanoparticulate delivery system that remains stable at physiological pH, owing to the disulfide bonds and surface crosslinking, and preferentially release of the encapsulated payload inside the tumor cells, where the glutathione concentrations can be a 1000-fold higher than the extracellular concentrations. 21, 22 From the results published so far, it is evident that the thiolated gelatin nanoparticles encapsulated with reporter plasmid DNA expressing green fluorescence protein (i.e., EGFP-N1) showed much higher transfection efficiency over gelatin nanoparticles in NIH-3T3 murine fibroblast cells. 23 In this study, the surface of both gelatin and thiolated gelatin nanoparticles was modified by reacting with methoxy-poly(ethylene glycol) (PEG)-succinimidyl glutarate (2000 Da) to prolong in vivo circulation time and achieve passive targeting by the enhanced permeability and retention (EPR) effect. 24 These modifications resulted in an increase in the mean nanoparticle hydrodynamic diameter to approximately 300 nm. The effective diameter was still o400-600 nm range required for accumulation in solid tumor by the EPR effect. [25] [26] [27] [28] The plasma circulation time of various nanoparticles after intravenous administration was determined and PEG-modified thiolated gelatin nanoparticles (PEG-SHGel) were found to have the longest circulation time (t 1/2 415 h) in plasma upon intravenous administration. Furthermore, between 13 and 15% of the recovered dose of PEG-SHGel nanoparticles accumulated in the tumor mass and remained there for up to 12 h. 29 Furthermore, we have examined systemic delivery and transfection potential of sFlt-1 expressing plasmid DNA in the control gelatin and thiolated gelatin (Gel and SHGel) and PEG-modified (PEG-Gel and PEG-SHGel) nanoparticles in vitro in MDA-MB-435 estrogen-negative human breast adenocarcinoma cells and in vivo in orthotopic tumor-bearing mice. 0 diaminobenzidine (DAB) substrate for peroxidase were obtained from BD PharMingen (Rockville, MD). b-Actin antibody and peroxidase-conjugated antirabbit immunoglobulin (IgG) antibody were obtained from Cell Signaling (Danvers, MA). Peroxidase-conjugated rabbit anti-goat antibody, peroxidase-conjugated goat anti-rat IgG antibody and normal goat serum were purchased from Jackson Immuno-Research (West Grove, PA). The estrogen-negative human breast adenocarcinoma cell line (MDA-MB-435) was obtained from American Type Culture Collection (ATCC, Manassas, VA) and maintained in Roswell Park Memorial Institute (RPMI)-1640 media with L-glutamine supplemented with 10% fetal bovine serum and 1% of penicillinstreptomycin.
Materials and methods

Materials
Preparation of plasmid DNA encapsulated PEGmodified nanoparticles Synthesis of thiolated gelatin. Thiolated gelatin, synthesized as reported previously, 23 by the covalent modification of the primary amino groups of type B gelatin with the addition of sulfahydryl moieties. Briefly, for the synthesis, 1.0 g of gelatin was dissolved in 100 ml of deionized water and then incubated with varying amount of 2-iminothiolane hydrochloride (up to 100 mg/g) at room temperature for 15 h. Any unreacted 2-iminothiolane was removed by repeated dialysis against 5 mM HCl, followed by 1 mM HCl solution for 24 h each. The purified thiolated gelatin was then dried in vacuo and stored at À801C for further use. The degree of thiolation of the modified gelatin was determined using the 5,5
0 -dithio-bis-(2-nitrobenzoic acid) (DTNB or Ellman's reagent) assay.
Preparation of DNA-containing nanoparticles. Based on our initial cytotoxicity and in vitro transfection results, 23 the nanoparticles for these studies were prepared with thiolated gelatin formed by reacting 20 mg of 2-iminothiolane per gram of gelatin, which resulted in 6.170.7 mmol of reduced -SH groups per gram of the biopolymer. The nanoparticles were prepared from 1% (w/v) aqueous solution of thiolated gelatin in a temperature-controlled water bath at 371C. The pH of the resulting solution was adjusted to 7.0 with 0.2 M sodium hydroxide, followed by the addition of sFlt-1 expressing plasmid DNA at a final concentration of 0.5% (w/w) of the polymer. A sample of human sFlt-1 expressing plasmid DNA was kindly provided by Professor Kensuke Egashira of Kyushu University (Fukuoka, Japan) 30 and was propagated and purified at Elim Biopharmaceuticals Inc. (Hayward, CA). The nanoparticles were formed when the solvent composition was changed from 100% water to 75% by volume of hydro-alcoholic solution upon gradual addition of absolute ethanol under continuous stirring conditions. The formed nanoparticles were further crosslinked with 0.1 ml of 40% (v/v) aqueous solution of glyoxal for the desired time interval and any unreacted aldehyde residues were quenched with 0.2 M glycine solution. The plasmid DNA-loaded nanoparticles were purified from the reaction mixture by a series of centrifugation and washing steps.
Surface modification of nanoparticles with PEG. The control gelatin (Gel) and thiolated gelatin (SHGel) nanoparticles collected after centrifugation were suspended in 0.1 M phosphate buffer (pH 7.4) and incubated with five times molar excess (2 mg of PEG per mg of gelatin or thiolated gelatin nanoparticles) of methoxy-PEG-succinimidyl glutarate (Mol. wt. 2000 Da) for 2 h at room temperature. At the end of the reaction, the nanoparticles were collected by centrifugation and assayed for the degree of PEG modification by using the TNBS assay. 31 With the TNBS assay, the percentage of surface-accessible amine groups that could react with TNBS was calculated. As methoxy PEG-succinimidyl glutarate reacts with the primary amine residues in Gel and SHGel nanoparticles, the degree of PEG modification was estimated indirectly based on differences between the absorbance values of TNBS in the supernatant with the unmodified and after PEG modification of gelatin and thiolated gelatin nanoparticles. For the in vivo transfection and efficacy studies, only PEG-modified nanoparticles were used as they showed long circulation times and highest accumulation at the tumor site in previous biodistribution studies. 29 Characterization of PEG-modified nanoparticles Particle size and surface charge measurements. The mean particle size, size distribution and surface charge of the unmodified and PEG-modified nanoparticles (i.e., PEG-Gel and PEG-SHGel) were analyzed using Zeta-PALS, 90Plus (Brookhaven Instruments Corporation, Holtsville, NY). The colloidal suspension of the nanoparticles was diluted with deionized distilled water and the particle size analysis was carried out at a scattering angle of 901 and at 251C. The zeta potential measurements were carried out at the default parameters of dielectric constant, refractive index and viscosity of water.
Electron spectroscopy for chemical analysis. In order to determine the surface presence of PEG chains on the modified nanoparticles, freeze-dried formulations of the nanoparticles were analyzed by electron spectroscopy for chemical analysis (ESCA) performed at the National ESCA and Surface Analysis Center for Biomedical Problems (NESAC/BIO), University of Washington (Seattle, WA). This technique analyzes the electrons that escape from the surface of the sample without loss of energy. For each surface chemical element, a spectrum was obtained by plotting the number of detected electrons as a function of the binding energy (in millivolts). High resolution analysis of the C 1S spectra was performed to determine the exact chemical composition from the hydrocarbon (C-C or C-H at 285 mV), ether (C-O at 286.4 mV) and the carbonyl (C ¼ O at 288.1 mV) envelops and the relative composition of each functionality was determined from the area under the peak. In PEG modified nanoparticles, the surface presence of ethylene oxide residues would translate into an increase in the C-O (ether) signal of the C 1S spectra. 32 Determination of sFlt-1 plasmid loading. The sFlt-1 encoding plasmid DNA containing nanoparticles were prepared as described above. The surface amine groups of the nanoparticles was then modified with PEG-SG, as previously described, and the remaining free amino groups were crosslinked with 40% (w/v) glyoxal solution followed by quenching with glycine. The loading efficiency of plasmid DNA in the nanoparticle formulations was determined by dissolving a known amount of the sample in protease (0.2 mg/ml)-containing phosphatebuffered saline (PBS, pH 7.4) at 371C. The plasmid DNA concentrations were quantified in aqueous solution using the fluorescent PicoGreen double-stranded DNA binding reagent (Molecular Probes, Eugene, OR) according to the supplier's instructions.
In vitro transfection studies in MDA-MB-435 breast cancer cells Cell culture conditions. MDA-MB-435 estrogen-negative human breast adenocarcinoma cell line derived from breast ductal carcinoma of a Caucasian female were obtained from ATCC. These cells were grown as a monolayer in culture using RPMI-1640 supplemented with L-glutamine, Pen-strep and fetal bovine serum at 371C and 5% CO 2 . MDA-MB-435 cells are metastatic in origin and they were also used to grow orthotopic tumors in athymic mice.
MDA-MB-435 cells were grown to semiconfluence in six-well cell culture plates containing with 2 Â 10 5 cells seeded per well. The freeze-dried sFlt-1 plasmid DNAcontaining nanoparticles were dispersed and diluted in serum-free medium. The untreated cells, those treated with naked sFlt-1 plasmid DNA and those treated with sFlt-1 plasmid DNA complexed with Lipofectin, a cationic lipid transfection reagent, were used as controls. The plasmid DNA-containing nanoparticle suspension was added at a concentration equivalent to 20 mg of plasmid DNA per well and incubated with the cells at 371C for a period of 6 h. Following this incubation period, the media was removed from each well and replaced with 2 ml of RPMI-1640. At pre-determined time points of 0.5, 1, 2, 4, 6 and 8 days, the cell culture supernatant was removed to determine the sFlt-1 expression.
Quantitative determination of transfection efficiency by ELISA. The concentration of expressed sFlt-1 protein secreted by the MDA-MB-435 cells into the culture medium was determined quantitatively with a Quantikine ELISA kit (R&D Systems) based on sandwich immunoassay technique. The media samples were diluted and added to the 96-well plate coated with a monoclonal antibody specific for VEGF R1/sFlt-1 and were allowed to incubate for 2 h. Any unbound sFlt-1 was removed by washing with a buffer and then incubated with an enzyme-linked polyclonal antibody specific for VEGF R1/sFlt-1. The excess of antibody-enzyme conjugate was washed off and the samples were then incubated with a substrate solution. Enzyme-catalyzed chromogen formation was quantified by measuring the visible absorbance at 450 nm. Using a calibration curve plotted with recombinant human sFlt-1, the concentrations of expressed sFlt-1 (in pg/ml) were calculated from the absorbance value following the control and nanoparticle-mediated cell transfection.
Qualitative determination of transfection efficiency by Western blotting. The concentrated cell culture supernatant samples at 48 h time point and the standards (recombinant human VEGF R1/Flt-1) were diluted using the Laemmli's SDS sample buffer. A pre-stained protein ladder (10-200 kDa), samples, and the standards were then electrophoresed on a pre-cast SDS polyacrylamide gel (7.5%) at 100 v for about 2 h using Trisgly SDS running buffer. At the end of electrophoresis, the cassette was cut open and the separated proteins were transferred onto nitrocellulose membrane at 60 v for 2 h using a transfer buffer containing 10% methanol. The membrane was washed for 30 min with three changes of wash buffer with PBS containing 0.05% Tween (TPBS) and blocked with 4% rabbit serum in TPBS for 1 h. After washing the blocking serum off the membrane, it was incubated with 0.1 mg/ml of antihuman VEGF-R1 (Flt-1) antibody overnight at 41C. The washings were repeated and the membrane was then incubated with 1:10 000 dilution of peroxidase-conjugated rabbit anti-goat antibody for 1 h with continuous shaking. Finally, the sample was placed in a working solution of ECL Western blotting chemiluminescent substrate. The excess substrate was removed and the membrane was exposed to X-ray film, which was developed to detect the bands on the Western blot.
In vivo transfection and therapeutic efficacy studies All of the experiments described below with athymic mice were approved by the Northeastern University's Institutional Animal Care and Use Committee. Six-week-old female Nu/Nu (athymic) mice, weighing approximately 20 g, purchased from Charles River Laboratories (Wilmington, MA), were used for the in vivo gene transfection and therapeutic efficacy studies. Upon arrival, the animals were housed in the Division of Laboratory Animal Medicine and supplied with sterile rodent pellets and acidified water ad libitum. The experimental animals were allowed to acclimate for at least 48 h before any experimentation.
Development of tumor model. An orthotropic human breast tumor xenograft model was developed by subcutaneous injection of 2.0 million MDA-MB-435 cells in 200 ml of normal saline in the mammary fat pad region of lightly isoflurane-anesthetized female Nu/Nu mice. The animals were monitored daily during tumor development by palpation of the injected region and by monitoring their weight and observing general motility pattern.
In vivo administration and determination of therapeutic efficacy. When the tumor volume had reached approximately, 40-45 mm 3 after 15 days post-inoculation, the animals were randomly divided into four groups as follows: (1) saline treated control group, (2) administration of naked sFlt-1 plasmid DNA administration in saline, (3) administration of sFlt-1 plasmid DNA encapsulated in PEG-modified gelatin nanoparticles and (4) administration of sFlt-1 plasmid DNA encapsulated in PEG-modified thiolated gelatin nanoparticles. The lightly-anesthetized animals in each group received intravenously, though the tail vein, an equivalent of 20 mg of sFlt-1 expressing plasmid DNA either as aqueous solution in saline (naked plasmid) or encapsulated in the nanoparticles on 1, 3 and 5 days. A total dose of 60 mg of plasmid DNA, therefore, was administered to each tumor-bearing animal. The change tumor volumes was determined using the following equation:
, where L and D are the shorter and longer tumor diameters, respectively.
Determination of in vivo transgene expression by ELISA and Western blotting. At the end of tumor treatment efficacy studies on day 40th following the start of treatment, the animals were killed by CO 2 inhalation and the tumor, liver and skeletal muscle tissues were excised. Each tissue was homogenized and the expression of sFlt-1 in the homogenate was measured quantitatively by ELISA using a Quantikine ELISA kit (R&D Systems) and qualitatively by Western blot analysis. The experimental methods for ELISA and Western blot were similar to ones used above for in vitro transfection studies (see In vitro Transfection Studies in MDA-MB-435 Breast Cancer Cells). For qualitative in vivo expression analysis by Western blotting, the control b-actin was detected from tumor tissues.
Detection and quantification of microvessel density by CD-31 immunostaining. The antiangiogenic efficacy of sFlt-1 plasmid DNA encapsulated nanoparticles was determined by CD-31 (PECAM-1) immunostaining and quantification of microvessel density in tumor cryosections according to published protocols. 33, 34 At the end of treatment efficacy studies, the tumor-bearing animals were killed by CO 2 inhalation and the excised tumor tissues were fixed in 2% paraformaldehyde overnight at 41C, washed twice with PBS and incubated with 30% sucrose for 1 day at 41C. The fixed tissues were frozen in tissue-Tek-OCT by immersing in ice-cold isopentane. The frozen tumor sections were cut into 8.0-mm thick slices with a cryostat maintained at À401C. For the microvessel density determination, the tumor sections were obtained from the same depth (i.
0 diaminodenzidine substrate, which in the presence of peroxidase, is converted into a brown colored chromogen. The tumor cryosections were then counterstained with hematoxylin and light microscopic images were obtained from the control and treated samples and processed using Adobe Photoshop software.
Following CD-31 staining, the quantitative microvessel density measurements were performed by counting the number of brown-stained blood vessels per field of view. The stained tissue sections were observed at a Â 20 magnification with a light microscope. The average number of stained blood vessels was counted from at least nine fields of observation (i.e., three animals per sample Â 3 fields of observation per tumor cryosection) and the results were converted into number of microvessels per mm 2 surface area.
Data analysis
All of the experimental data were subjected to statistical Student's t-test analysis for comparing the results of two samples. For comparing the results of more than two samples, analysis of variance (ANOVA) was performed. Data were considered statistically significant at 95% confidence interval (i.e., Po0.05).
Results
Based on our earlier studies that showed high in vitro transfection efficiency of gelatin and thiolated gelatin nanoparticles with reporter plasmid expressing green fluorescent protein (EGFP-N1) and b-galactosidase (CMV-b) 23, 35 in this study we examined the potential for transfection in vitro and in vivo of therapeutic plasmid expressing soluble Flt-1 receptor (VEGF-R1) for antiangiogenic effect. Thiolated gelatin, synthesized by reacting type B gelatin with 2-aminothiolane and characterized by Ellman's assay, was used to prepare nanoparticles using a solvent exchange protocol developed and optimized in our laboratory. 19, 36 As shown in Figure 1 , the thiolated gelatin (SH-Gel) nanoparticles were spherical and had an effective diameter of approximately 200-250 nm with a smooth surface. In addition, the rhodamine dextran-containing nanoparticles were efficiently internalized in a variety of cell lines, including proliferating cells (Figure 1b) . Lastly, when EGFP-N1 plasmid was encapsulated in the SH-Gel nanoparticles, efficient in vitro transfection was observed relative to unmodified gelatin (Gel) nanoparticles or Lipofectincomplexed plasmid DNA (Figure 1c) .
When Gel and SH-Gel nanoparticle surfaces were functionalized with methoxy-PEG-succinimidyl glutarate at pH 7.4, the average effective diameters of the PEGmodified nanoparticles increased to between 290 and 320 nm. PEG derivative reacts with the free primary epsilon-amino groups of the basic amino acids in gelatin and thiolated gelatin. Using 5 M excess of PEG as compared with the gelatin or thiolated gelatin, 90% of the surface available amine groups were found to be modified as measured by the TNBS assay when the reaction proceeded for 2 h at room temperature. The surface charge (zeta potential) values on the Gel and SHGel nanoparticles were found to be À8.45 and À9.36 mV, Gelatin-based nanovectors for sFlt-1 gene delivery S Kommareddy and M Amiji respectively. In comparison, upon PEG modification, both PEG-Gel and PEG-SHGel nanoparticles had a surface charge of À7.72 and -6.67 mV, respectively. Importantly, the size and surface charge of the both unmodified and PEG-modified nanoparticles did not change upon encapsulation of plasmid DNA. Lastly, PEG surface modification of the nanoparticles was confirmed by ESCA studies. The increase in the relative peak intensities of C-O (ether) linkage in the high resolution C1s spectra is indicative of the surface presence of PEG chains. 37 The relative area-under-the-peak due to C-O signature in the C1s spectra was 79.2% for PEG-Gel nanoparticles and 82.6% for PEG-SHGel nanoparticles. In contrast, the relative areas-under-the-peak owing to C-O signature in the control Gel and SH-Gel nanoparticles were 36.0 and 28.4%, respectively. 29 After encapsulation of sFlt-1 expressing plasmid DNA in Gel nanoparticles, the loading efficiency at 0.5% (w/w) DNA incorporation was found to be 99.5%. The DNA loading efficiency remained at approximately 99% even after PEG-modification of Gel nanoparticles. For SH-Gel nanoparticles, the loading efficiency was slightly lower at 94.4% and decreased even further to 91.7% upon PEG modification.
Following in vitro transfection in MDA-MB-435 cells, the soluble protein expressed in the cell culture supernatant was quantitatively and qualitatively analyzed by ELISA and Western blot analysis, respectively. A sandwich immunoassay technique was used to estimate the expressed sFlt-1 in cell culture supernatants using 96-well plates coated with a monoclonal antibody specific for human VEGF-R1/sFlt-1. From the quantitative analysis of transfection results by ELISA, presented in Figure 2a , it is clear that the cells in culture treated with plasmid DNA delivered either as Lipofetin-complexes or encapsulated in Gel, SHGel, PEG-Gel or PEG-SHGel nanoparticles resulted in significant transfection and expression of the secreted sFlt-1. The highest transfection efficiencies were observed with PEG-Gel and PEG-SHGel nanoparticle-mediated DNA delivery. A single 20 mg plasmid DNA dose in the PEG-modified nanoparticles resulted in sFlt-1 levels of 450 and 550 pg/ml when administered in PEG-Gel and PEG-SHGel nanoparticles, respectively, after 8 days. Furthermore, qualitative confirmation of sFlt-1 expression was obtained by Western blot analysis of the protein using specific antibodies and the results are shown in Figure 2b . After 48 h posttransfection, the cell culture supernatant was concentrated and loaded in the respective lanes for electrophoresis and antibody-mediated separation. In lanes 1 and 2, the bands correspond to the expressed sFlt-1 following transfection with Gel and SHGel nanoparticles, respectively. In lanes 3 and 4, the bands correspond to the expressed sFlt-1 following transfection with PEG-Gel and PEG-SHGel nanoparticles, respectively. Additionally, in lane 5, the expressed sFlt-1 following transfection with Lipofectin-DNA complex is shown. The expressed sFlt-1 band from the MDA-MB-435 cells that were transfected with naked plasmid DNA is shown in lane 6. Lane 7 band represents culture supernatant from cells that did not receive any treatment (negative control) and lane 8 was loaded with recombinant human sFlt-1 protein (positive control).
In the second part of the study, the in vivo transfection efficiency following intravenous administration of the sFlt-1 expressing plasmid DNA and the antiangiogenic efficacy was evaluated in human breast adenocarcinoma (MDA-MB-435) implanted orthotopically in the mammary fat pad of female Nu/Nu (athymic) mice. When the tumors reached a volume of 40-45 mm 3 , the animals were injected with three doses of the control (naked plasmid DNA) and PEG-modified nanoparticles containing sFlt-1 expressing plasmid (20 mg of plasmid DNA per dose per time). The expression of sFlt-1 in the tumor, liver and skeletal muscle tissues was confirmed quantitatively by ELISA and qualitatively by Western blot analysis (Figure 3) . The concentration of expressed sFlt-1 was determined in picograms and normalized to the protein content of the tissues. About 15 and 13% of the recovered dose of PEG-SHGel and PEG-Gel nanoparticles, respectively, were retained in the tumor for up to 12 h post-intravenous administration in MDA-MB-435 tumor-bearing mice. 29 As shown in Figure 3a , intravenous administration of sFlt-1 plasmid DNA encapsulated in PEG-SHGel nanoparticles resulted in the highest expression efficiency in the tumor of 1134 pg/mg after 40 days post-tumor implantation. From our biodistribution studies in MDA-MB-435 tumor-bearing mice, around 25-35% of the administered dose of PEG-SHGel nanoparticles were taken up by the liver following systemic administration. 29 As such, it was not surprising that liver tissue also showed relatively high transfection efficiency of 1015 pg/mg when the plasmid was administered in PEG-SHGel nanoparticles. Skeletal muscle does not accumulate any nanoparticles following intravenous administration and we did not see any transgene expression in this tissue. When sFlt-1 expressing plasmid was administered in PEG-Gel nanoparticles, the transgene expression results in the tumor were also reasonably good. For instance, after 40 days following tumor implantation and treatment, sFlt-1 levels of 630.2 pg/mg were measured in the tumor mass. However, PEG-Gel accumulates to a greater extent (B50% of recovered dose) in the liver as compared with PEG-SHGel and, therefore, there was greater sFlt-1 transfection level in the liver of 1677 pg/mg following intravenous administration. Systemic administration of naked plasmid DNA did not result in significant expression in the tumor, but did show high liver transfection.
The quantitative in vivo expression results of ELISA were further confirmed with qualitative Western blot bands of expressed sFlt-1 from tissue homogenates. The Western blot results and are shown in Figure 3b . The chemiluminescent bands were visualized by exposure to X-ray film and these clearly indicate expression of sFlt-1 in tumors treated with plasmid DNA encapsulated in PEG-SHGel and PEG-Gel nanoparticulate formulations. In these studies, naked plasmid DNA expressed very low levels of protein in the tumor to be visualized by Western blot analysis. However, there was high liver expression with naked plasmid DNA expressing sFlt-1. Although PEG-Gel nanoparticles did enhance tumor expression of sFlt-1 as compared with administration of naked plasmid DNA, the levels of sFlt-1 with PEG-Gel were not as high as with PEG-SHGel. PEG-SHGel nanoparticles afforded the highest expression efficiency in the tumor mass. Skeletal muscle as a non-target tissue did not express any protein. From the ELISA and Western blot results of untreated animals, a residual activity of sFlt-1 was observed. This observed residual activity could actually be due to nonspecific activity of the primary monoclonal antibody with the tissue homogenates. In the Western blot analysis, endogenous b-actin expression from the tumor tissues was used as controls.
The results of antiangiogenic efficacy studies (Figure 4 ) indicate the ability of PEG-Gel and PEG-SHGel nanoparticles as vehicles for therapeutic gene delivery to human breast adenocarcinoma implanted orthotopically in nude mice. In the case of animals treated with DNAcontaining PEG-SHGel nanoparticles, the tumor volumes at the end of the study (32. ). On the other hand, animals treated with plasmid DNA encapsulated in PEG-Gel nanoparticles resulted in tumors with a doubling time of approximately 19 days from the start of treatment, followed by naked plasmid DNA-treated animals and untreated animals that had the tumor volume doubling times of 16 days and 13 days, respectively. The images of the excised tumors shown in Figure 4 show the relative comparison between the control and treated tumor mass. From these images, it is clear that the expressed sFlt-1 was effective in suppressing tumor growth in MDA-MB-435 xenograft model.
Intravenous administration PEG-modified gelatin and thiolated gelatin nanoparticles containing sFlt-1 plasmid to MDA-MB-435 tumor-bearing mice resulted in significant reduction in the tumor neo-vasculature, as shown by CD-31 immunostaining of the tumor cryosections. The microvessel density in tumor tissue cryosections was obtained by counting the number of stained blood vessels per field are shown in Figure 5 . The quantitative results of microvessel density per mm 2 surface area is shown in Figure 5a . From these results, systemic administration of slFt-1 expressing plasmid DNA in PEG-SHGel nanoparticles resulted in the lowest average microvessel density of only 92 vessels per mm Qualitative light microscopy images of CD-31 immunostained tumor crysections from the untreated control, intravenous administration of naked plasmid DNA, and plasmid DNA administration in PEG-modified nanoparticle formulations are shown in Figure 5b . For these images, the tumor cryosections were prepared by incubation with primary antibodies against platelet endothelial cell adhesion molecule-1 (PECAM-1) on surface of endothelial cells of mice and staining with DAB and hematoxylin. The blood vessels lined with endothelial cells were stained brown owing to the colorimetric reaction of DAB reagent with the enzyme peroxidase. When compared with the sections of tumors treated with DNA encapsulated in PEG-modified nanoparticles, both the untreated tumors and tumors treated with naked plasmid DNA showed high prominence of blood vessels throughout the tissue. In addition to highly developed blood vessels, the untreated tumors also had clusters of tiny blood vessels in the tissue cryosections. In contrast, very few blood vessels could be observed when sFlt-1 plasmid DNA was administered in PEG-Gel and PEG-SHGel nanoparticles.
Discussion
There is tremendous potential of gene therapy for systemic diseases, such as cancer, if a safe and effective delivery vector can be designed.
1 This is especially important for antiangiogenic therapy, where a number of potential candidates are protein-based drugs. 4, 7 Development of protein therapeutics for chronic systemic delivery is associated with significant problems, such as poor stability, invasive systemic delivery, inadequate transport properties to the disease site, non-target effects and high cost. Viral vectors are used in over 70% of current clinical protocols of gene therapy. Viruses, however, are plagued with a number of toxicity and manufacturing issues, such as integration with host genome, generation of potent immunity, limitations on the size of incorporated payload, poor batch-to-batch reproducibility and scale-up concerns. 38 As such, there is a need to develop safe and effective non-viral gene delivery vehicles for systemic administration.
Over the last several years, our lab has pioneered the development of gelatin-based nanoparticles for systemic gene delivery. 19, 20, 23, 35, 39 Gelatin is a biocompatible and biodegradable material, predominantly obtained from acidic or alkaline hydrolysis of bovine and porcine collagen. It has a long history of safe use in pharmaceutical, cosmetics and food products. With concern over the toxicities with animal-derived products, several companies are now manufacturing gelatin by recombinant DNA technology. For gene delivery applications, type B gelatin was intentionally selected in our studies because it has an isoelectric point of about 4.5. When nanoparticles are made from type B gelatin by the solvent exchange method at pH 7.0, there is a net negative charge on the biopolymer. We have used this system to insure that the nanoparticles are physically encapsulating plasmid DNA rather than electrostatically complexing with it. Poor transfection efficiency with cationic polymer-and lipid-DNA electrostatic complexes is usually due to their accumulation at the nuclear membrane after cellular internalization. In addition, cationic polymers and lipids are also highly toxic to cells and tissues. 40 We hypothesized that type B gelatin nanoparticles would be a relatively safe vector system, where the encapsulated Gelatin-based nanovectors for sFlt-1 gene delivery S Kommareddy and M Amiji plasmid DNA structure was maintained in the supercoiled state at the nuclear membrane for efficient nuclear import. As the nuclear membrane pore diameter in nondividing cells is o20 nm, supercoiled plasmid would be able to penetrate into the nucleus more effectively than a linear or open circular plasmid. In addition, effective release of the plasmid in the cytosol and near the nucleus was also an important requirement. Based on these design criteria for systemic gene delivery, we have formulated thiolated gelatin nanoparticles.
In this study, we have modified the surface of thiolated gelatin nanoparticles with PEG chains to enhance the circulation times in the body upon systemic administration and allow for preferential tumor accumulation by the EPR effect. Upon PEG modification, we observed an increase in the effective diameter of the nanoparticles from 220-250 to around 320 nm. However, the effective diameter of PEG-modified nanoparticles was still smaller than the 400-600 nm pore size of the tumor blood vessels as measured by Jain and co-workers. 26 Surface presence of PEG chains on the modified nanoparticles was confirmed from the C1s spectra of ESCA. When administered intravenously in MDA-MB-435 tumorbearing mice, approximately 13 and 15% of the recovered dose of PEG-Gel and PEG-SHGel, nanoparticles, respectively, accumulated in the tumor mass. In addition, PEGSHGel nanoparticles had an in vivo half-life of over 15 h in plasma and over 37 h in the tumor mass. 29 The results of quantitative and qualitative sFlt-1 transfection in MDA-MB-435 cells show very high efficiency of transgene expression with the plasmid DNA encapsulated in PEG-modified nanoparticles relative to the unmodified nanoparticles and other controls. The unmodified and PEG-modified nanoparticles were internalized in the tumor cells to the same extent by nonspecific endocytotic pathway. The higher efficiency of in vitro transfection with PEG-modified nanoparticles is probably due to greater stability of the encapsulated plasmid during intracellular transport, and especially in the endosome/lysosome compartments. PEG-SHGel nanoparticles afforded the most pronounced transgene expression that continued to increase for up to 8 days following administration of a single 20 mg DNA dose. Although DNA-complexed with Lipofectin, a commercially available cationic lipid-based transfection reagent, was effective initially, there was a significant decline after 4 days owing to higher cytotoxicity. The lowest transfection efficiency was observed with naked plasmid DNA, which does not enter the cells or gets degraded very quickly. The quantitative ELISA results were confirmed by qualitative Western blot analysis. When compared with recombinant human sFlt-1 protein band, the soluble protein secreted by cells was found to be running at slightly lower molecular weights. This could be due to differences in post-translational modification of the protein in the human breast cancer cell line (MDA-MB-435).
Following intravenous administration in female Nu/Nu mice bearing orthotopic MDA-MB-435 human breast cancer xenograft, there was statistically significant (Po0.05) enhancement in tumor transfection when the plasmid DNA was delivered with the PEG-Gel and PEG-SHGel nanoparticles as compared with naked plasmid DNA. In addition, as about 50 and 35% of the administered dose of PEG-Gel and PEG-SHGel nanoparticles, respectively, did accumulate in the liver, we did see relatively high transfection efficiency in the liver tissue as well. 29 When compared with plasmid delivered in PEGGel nanoparticles, the liver transfection with plasmid in PEG-SHGel was lower. There was no transfection of sFlt-1 in the skeletal muscle, a non-target tissue, upon administration in any of the formulations. This shows that the significant potential of the nanoparticulate systems in directing the DNA delivery to specific disease targets following intravenous administration. These qualitative and quantitative results were extremely encouraging for the utility of PEG-SHGel nanoparticles as systemic gene delivery vector. Further studies to examine the therapeutic antiangiogenic efficacy of transfected sFlt-1 were carried out. When compared with the naked plasmid DNA-treated tumor-bearing animals, there was significant (Po0.05) tumor growth suppression when the sFlt-1 plasmid DNA was administered in PEG-modified nanoparticles. In comparison with PEG-Gel, PEG-SHGel nanoparticle formulation was more effective in suppressing tumor growth. A 60 mg total dose administered over 3 days effectively suppressed tumor growth to an average of 40 mm 3 volume for up to 28 days post-administration of sFlt-1 plasmid DNA in PEG-SHGel nanoparticles. This may be due to greater tumor accumulation and more effective intracellular plasmid delivery in the highly reducing cellular environment with the PEGSHGel nanoparticles as compared with PEG-Gel nanoparticles.
The antiangiogenic effect of expressed sFlt-1 was confirmed by CD-31 immunostaining of the tumor cryosections and quantitative determination of microvessel density. From these studies, it is clear than sFlt-1 was able to significantly suppress tumor neo-vasculature formation when the plasmid DNA was administered in PEG-Gel and PEG-SHGel nanoparticles. The most pronounced effect on microvessel density was observed with the plasmid administered in PEG-SHGel nanoparticles. This is probably due to the long circulating property of PEG-modified nanoparticles, preferential uptake of thiolated gelatin nanoparticles by tumors, enhanced stability of DNA during intracellular transport, and efficient nuclear uptake resulting in sustained production of the therapeutic protein at the tumor site.
Conclusions
The in vitro and in vivo sFlt-1 plasmid DNA transfection results presented in this study confirm the enormous potential of PEG-Gel and PEG-SHGel nanoparticles as safe and effective systemic gene delivery vehicles to solid tumor. Both of these PEG-modified nanoparticle systems allow for long circulation times in the body and promote passive tumor targeting owing to the hyper-permeability of the microvasculature by the EPR effect. Owing to enhanced tumor-specific delivery following systemic administration and improved intracellular stability and nuclear uptake of the encapsulated plasmid DNA, there was very high levels and sustained transfection observed in vivo in an orthotopic tumor xenograft model. Additionally, the expressed sFlt-1 was therapeutically active as shown by tumor growth suppression and decrease in neo-vasculature as measured by microvessel density determinations. Overall, this study shows that a noncomplexing DNA delivery vehicle, such as PEG-SHGel nanoparticles, can serve as a safe and effective platform for systemic administration of therapeutic plasmid to solid tumors.
